Johnson & Johnson Halts Phase II Dengue Study Amid Shift in R&D Priorities

Study Termination:
Johnson & Johnson (JNJ) has discontinued its Phase II field study evaluating the efficacy of mosnodenvir, an experimental antiviral drug, for preventing dengue virus in adults aged 18-65 years.

Reason for Termination:
The decision is part of a strategic reprioritization of JNJ's Communicable Diseases research and development (R&D) portfolio.

Safety Record:
No safety issues were identified during the study, and previous Phase I and Phase IIa trials showed mosnodenvir to be safe and well-tolerated.

Efficacy Data:
Efficacy results from the Phase II field study will be available once the final data analyses are complete and will be shared with the medical community.

R&D Focus:
JNJ is focusing on other areas, including immunology, neuroscience, cardiovascular health, metabolism, and oncology, with significant investments in these fields.

Market Impact:
JNJ's stock has appreciated by 2.3% this year, compared to an 18.5% rise in the industry, and the company holds a Zacks Rank of #4 (Sell).